The CDC recently updated RSV vaccine recommendations to include certain adults aged 50 and up. When is the best time to get ...

The COVID booster currently available is based on the JN.1 subvariant. Nimbus is a direct descendant of JN.1 – as is another ...

Sanofi has struck a deal to buy Vicebio for $1.15 billion upfront, securing preclin | Sanofi has struck a deal to buy Vicebio ...

The acquisition, which will give Sanofi a combination vaccine for respiratory syncytial virus and human metapneumovirus, ...

A new respiratory syncytial virus vaccine to protect infants from severe illness is available in South Africa’s private sector, but not yet in public clinics. The country’s advisory group on ...

Two recent studies published this week assess the low uptake of respiratory syncytial virus (RSV) vaccine among US veterans ...

Each year in the UK, 30,000 children under the age of five are hospitalised with RSV and it causes around 30 infant deaths.

Sanofi is buying Vicebio for more than $1 billion, picking up an experimental vaccine targeting RSV and another respiratory bug.

Sanofi is buying Vicebio, a biotech, that is developing vaccines for two viruses using the molecular clamp technology ...

STAFF WRITERS GIPPSLANDERS are being urged to protect themselves and their loved ones against flu and respiratory syncytial ...

The vaccine candidate complements Sanofi’s position in the respiratory vaccines space where the company is present in flu and RSV prevention. It allows Sanofi to offer increased physician and patient ...

Sanofi has announced that it will be expanding its respiratory vaccines pipeline by acquiring UK-based Vicebio for up to ...